Topic: Alzheimer.
Destination: The fund aims to de-risk clinical programs by supporting clinical trials with clear go/no-go criteria and if positive, sufficient data to encourage follow on funding of the approach. Programs will be considered that test novel or repurposed drug candidates or devices in phase 1 or phase 2 clinical trials for FTD disorders, led by academic researchers or biotechnology companies. Both disease-modifying and symptomatic approaches will be accepted.
Budget: Up to $2,000,000 based on stage and scope of the trial.
Duration: Not indicated.
Fill out the form below to receive more information: